Gansu New Silk Road Industrial Investment Co., Ltd. was established in January 2015. It is a wholly owned subsidiary of Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd. (stock abbreviation: Longshenrongfa, stock code: 300534) and it is mainly engaged in domestic and overseas project investment, asset management, goods import and export, technology import and export, import and export business as agent, import  and sale of prepackaged foods and other businesses. With the development philosophy of "wide consultation, joint contribution and shared benefits", the company actively participates in quality equity investment projects in China, carry out TCM promotion, culture exchange and scientific research projects abroad, overseas operation of TCM diagnosis and treatment centers, overseas registration of TCM, overseas investment in TCM industry, import and export activities, investment in quality projects in China and TCM international health tourism projects etc. To actively respond to the "Belt and Road" initiative and catch the opportunity brought by the initiative, the company actively explored the TCM markets in Central Asia, Southeast Asia, Europe and other countries, promote the drug registration and related business cooperation of Long Shenrong's traditional Chinese medicine varieties in the four countries of Central Asia and Thailand； it successfully registered 6 TCM products in the name of active additives in Russia, 4 kinds of proprietary Chinese medicine products in the category of medicine in Singapore; carry out import and export trade of Chinese herbal medicines with South Korea, Taiwan and Indonesia.We have rich experience in pharmaceutical import and export trade.   The company actively promotes the overseas promotion and application of Chinese medicine, promotes the development of Chinese medicine in overseas markets, and deepens substantive cooperation in the field of Chinese medicine at home and abroad, as well as other cooperation in the fie